Raymond Chapman, MD
Internal Medicine · Hartsville, SCNPI 1699707281
Payments from drug & device makers
Across 290 payments — averaging $16.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$773
- Novo Nordisk$513
- Pfizer$455
- Boehringer Ingelheim$342
- AstraZeneca$307
- Novartis$288
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,60098%
- Education$1122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $773 |
| Novo Nordisk | 33 | $513 |
| Pfizer | 31 | $455 |
| Boehringer Ingelheim | 19 | $342 |
| AstraZeneca | 19 | $307 |
| Novartis | 16 | $288 |
| Lilly USA, LLC | 22 | $281 |
| Astellas Pharma US Inc | 11 | $255 |
| Bayer | 14 | $191 |
| Amgen | 11 | $181 |
| Amarin Pharma, Inc. | 10 | $166 |
| GSK | 9 | $126 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Nestle Healthcare Nutrition Inc. | 5 | $83 |
| Abbott | 5 | $79 |
| E.r. Squibb & Sons, L.L.C. | 5 | $65 |
| Merck | 4 | $50 |
| Exact Sciences | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $25 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Cranial Technologies, Inc | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| Tris Pharma Inc | 1 | $17 |
| Antares Pharma, Inc. | 1 | $17 |
| Boston Scientific | 1 | $16 |
| Radius Health, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
How this compares
$4,712 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 595 | $322,800 |
| TrulicityDulaglutide | 210 | $261,022 |
| OzempicSemaglutide | 169 | $257,225 |
| EliquisApixaban | 391 | $197,794 |
| KerendiaFinerenone | 108 | $105,983 |
| Humira(Cf) PenAdalimumab | 11 | $74,927 |
| MounjaroTirzepatide | 59 | $67,956 |
| RexultiBrexpiprazole | 60 | $56,524 |
| LinzessLinaclotide | 72 | $49,709 |
| EntrestoSacubitril/Valsartan | 92 | $44,090 |
| ProliaDenosumab | 20 | $34,578 |
| XareltoRivaroxaban | 49 | $33,499 |
| XifaxanRifaximin | 17 | $33,046 |
| MyrbetriqMirabegron | 67 | $27,503 |
| VascepaIcosapent Ethyl | 40 | $25,185 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $342 | $334,708611 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $281 | $328,978269 claims |
| Novo NordiskOzempic | $513 | $257,225169 claims |
| PfizerEliquis | $455 | $197,794391 claims |
| BayerKerendia | $191 | $105,983108 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $84 | $56,52460 claims |
| AbbVieLinzess | $773 | $49,70972 claims |
| NovartisEntresto | $288 | $44,09092 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $307 | $41,111123 claims |
| Johnson & JohnsonXarelto, Invega Sustenna | $25 | $40,95961 claims |
| AmgenProlia | $181 | $34,57820 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $30 | $33,04617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Hartsville
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
- Jerry BackNorth Charleston$322K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.